Researchers are conducting a clinical study to investigate whether cannabigerol (CBG)—a naturally occurring cannabinoid found in hemp—may help support individuals diagnosed with Attention‑Deficit/Hyperactivity Disorder (ADHD). ADHD is a common neurodevelopmental condition that can affect attention, impulse control, and executive functioning. This trial, registered with the U.S. National Institutes of Health, aims to gather controlled human data on how CBG affects cognitive and behavioral symptoms associated with ADHD, as well as its safety and tolerability in adult participants.

Participants in the study receive CBG under monitored conditions and complete assessments designed to measure changes in attention, impulsivity, mood, and other related outcomes over time. The research also tracks any side effects or changes in daily functioning, with the goal of helping scientists better understand how CBG interacts with the nervous system and whether it may influence pathways involved in attention and self‑regulation. Unlike observational studies or lab research, this trial offers structured clinical evaluation, which is important for determining real‑world effects in people.

While results have not yet been published, this clinical trial represents an important step toward evaluating whether CBG could be a promising supportive option for adults with ADHD, especially for those interested in non‑traditional approaches. The findings may contribute to future research and help inform how cannabinoid‑based therapies might be used in supportive care for cognitive and behavioral symptoms.

Source

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder. ClinicalTrials.gov Identifier: NCT06115603. National Institutes of Health (NIH). Available at: https://clinicaltrials.gov/study/NCT06115603